DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
DexCom
DXCM
Hutchmed (China)
HCM
New Fortress Energy
NFE
Enerpac Tool
EPAC
US Stock MarketDetailed Quotes
GERN Geron
- 2.560
- -0.230-8.24%
Close Feb 14 16:00 ET
- 2.580
- +0.020+0.78%
Post 19:59 ET
1.55BMarket Cap-8.00P/E (TTM)
2.835High2.520Low23.22MVolume2.800Open2.790Pre Close60.46MTurnover4.40%Turnover RatioLossP/E (Static)604.50MShares5.34052wk High5.29P/B1.35BFloat Cap1.64052wk Low--Dividend TTM527.58MShs Float75.875Historical High--Div YieldTTM11.29%Amplitude0.750Historical Low2.603Avg Price1Lot Size
Geron Stock Forum
Oh yes. I have a favorite here. Reminds me of something a long time ago
Pain staking searches will always produce results. Patience is a virtue. Combining both makes for powerful decision-making
1. My strategy is to find an item that has immediate results in order to sell and recuperate the initial investment by selling 50% of the initial shares purchased. (SureBet!)
2. Leaving the remaining 50% to hit as a limit sale at the obnoxious goal mi...
Company says Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treat...
3 mins ago
Geron Announces Phase 1 Findings From Two-Part Improvemf Study Presented at Ash Suggesting Tolerability of Rytelo™ (Imetelstat) in Combination With Ruxolitinib as Frontline Therapy in Patients With Myelofibrosis
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet